02.02.2023 07:00 | GSK | Daprodustat approved by US FDA for anaemia of CKD | RNS |
01.02.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
01.02.2023 15:00 | GSK | Total Voting Rights | RNS |
01.02.2023 09:09 | HLN, GSK | TOP NEWS: GSK profit grows as aims for first-ever approved RSV vaccine | Alliance |
01.02.2023 07:05 | GSK | Benlysta granted Orphan Drug Designation by US FDA | RNS |
01.02.2023 07:00 | GSK | Final Results | RNS |
31.01.2023 12:54 | GSK, HLN | Haleon appoints Pfizer Chief Financial Officer David Denton to board | Alliance |
25.01.2023 15:45 | VOD, VMUK, UKCM | UK earnings, trading statements calendar - next 7 days | Alliance |
18.01.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
18.01.2023 11:10 | IPO, GSK | IN BRIEF: IP Group appoints GSK's Anita Kidgell as non-executive | Alliance |
17.01.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
16.01.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
13.01.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
12.01.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
05.01.2023 15:41 | TRY, SSE, SNWS | UK dividends calendar - next 7 days | Alliance |
05.01.2023 09:05 | GSK | IN BRIEF: WuXi Biologics signs exclusive deal with GSK | Alliance |
03.01.2023 15:00 | GSK | Total Voting Rights | RNS |
03.01.2023 09:24 | DRX, HIK, WIZZ | LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH | Alliance |
22.12.2022 15:30 | GSK | Director/PDMR Shareholding | RNS |
21.12.2022 15:35 | GSK | Director/PDMR Shareholding | RNS |
21.12.2022 15:30 | GSK | Director/PDMR Shareholding | RNS |
15.12.2022 15:30 | GSK | Board and Committee Changes | RNS |
13.12.2022 15:30 | GSK | Director/PDMR Shareholding | RNS |
08.12.2022 09:48 | TTG, XPP, VLX | LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG | Alliance |
07.12.2022 07:00 | GSK | Statement: Zantac (ranitidine) litigation | RNS |
06.12.2022 21:59 | HLN, GSK | TOP NEWS: GSK welcomes Zantac legal boost in Florida | Alliance |
05.12.2022 16:00 | GSK | Transfer of Treasury Shares | RNS |
05.12.2022 10:00 | WJG, AIBG, FERG | LONDON BROKER RATINGS: Jefferies cuts Persimmon; BoA cuts GSK | Alliance |
02.12.2022 15:30 | GSK | Director/PDMR Shareholding | RNS |
02.12.2022 09:38 | ROO, JET, THG | LONDON BROKER RATINGS: Jefferies raises AJ Bell to 'buy' from 'hold' | Alliance |
02.12.2022 08:47 | GSK | TOP NEWS: GSK gets EMA validation for bone marrow cancer treatment | Alliance |
02.12.2022 07:00 | GSK | EMA file accepted for momelotinib | RNS |
02.12.2022 07:00 | GSK | Jemperli positive trial in endometrial cancer | RNS |
01.12.2022 15:00 | GSK | Total Voting Rights | RNS |
25.11.2022 16:47 | GSK | Publication of Final Terms of EMTN Notes | RNS |
24.11.2022 15:00 | GSK | GSK publishes provisional 2023 dividend dates | RNS |
22.11.2022 16:00 | GSK | Publication of Supplementary EMTN Prospectus | RNS |
22.11.2022 08:41 | GSK | TOP NEWS: GSK suffers setback as FDA demands withdrawal of cancer drug | Alliance |
22.11.2022 07:00 | GSK | Blenrep US Update | RNS |
21.11.2022 15:30 | GSK | Director/PDMR Shareholding | RNS |
18.11.2022 16:00 | GSK | Publication of EMTN Supplementary Prospectus | RNS |
15.11.2022 16:00 | GSK | Block listing Interim Review | RNS |
15.11.2022 15:53 | GSK | Final results of outstanding Notes Tender Offer | RNS |
15.11.2022 09:58 | AMS, RWI, ITM | LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform' | Alliance |
15.11.2022 07:00 | GSK | Interim results of outstanding Notes Tender Offer | RNS |
11.11.2022 10:44 | GSK | GSK to restrict US use of cancer drug Zejula to some populations | Alliance |
11.11.2022 07:00 | GSK | GSK Update: Zejula 2L in US | RNS |
10.11.2022 18:10 | GSK | Sanofi-GSK COVID booster vaccine approved by EU | RNS |
10.11.2022 15:54 | YNGA, VLX, GSEO | UK dividends calendar - next 7 days | Alliance |
10.11.2022 15:30 | GSK | Director/PDMR Shareholding | RNS |
10.11.2022 09:00 | GSK | Block Listing Application | RNS |
08.11.2022 09:39 | AFM, ITM, WIZZ | LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson | Alliance |
08.11.2022 09:26 | GSK | Launch of Tender Offer for outstanding Notes | RNS |
07.11.2022 08:59 | GSK | GSK looks to combination trials as cancer drug fails to meet endpoint | Alliance |
07.11.2022 07:00 | GSK | DREAMM-3 phase III trial for Blenrep | RNS |
04.11.2022 08:08 | GSK, AZN | TOP NEWS: AstraZeneca's Beyfortus wins EU approval for RSV in newborns | Alliance |
03.11.2022 13:00 | GSK | Publication of Suppl.Prospcts | RNS |
03.11.2022 09:13 | GSK | GSK halts enrolment early for UTI trials; moves to regulatory approval | Alliance |
03.11.2022 07:00 | GSK | IDMC recommends gepotidacin early efficacy stop | RNS |
02.11.2022 09:26 | HLN, GSK | TOP NEWS: GSK ups annual guidance on "excellent" quarterly performance | Alliance |
02.11.2022 07:01 | GSK | 3rd Quarter Results | RNS |
02.11.2022 07:00 | GSK | GSK RSV vaccine: US FDA Priority Review | RNS |
01.11.2022 15:00 | GSK | Total Voting Rights | RNS |
31.10.2022 14:28 | GSK, HLN | Haleon announces results for exchange offers from GSK spin-off | Alliance |
28.10.2022 08:44 | GSK | TOP NEWS: GSK gets support from European panel for HIV prevention | Alliance |
28.10.2022 07:00 | GSK | EMA validates MAA for cabotegravir LA for PrEP | RNS |
28.10.2022 07:00 | GSK | EMA accepts GSK RSV older adult vaccine for review | RNS |
27.10.2022 10:02 | GSK | US FDA advisory panel votes against GSK kidney drug use in some cases | Alliance |
27.10.2022 07:05 | GSK | GSK announces FDA meeting outcome on daprodustat | RNS |
27.10.2022 07:00 | GSK | ContRAst phase III programme for otilimab update | RNS |
26.10.2022 15:53 | WIZZ, WEIR, SKG | UK earnings, trading statements calendar - next 7 days | Alliance |
25.10.2022 10:00 | GSK | Board Committee Changes | RNS |
24.10.2022 10:28 | GSK, SAR | IN BRIEF: Sareum widens annual loss; considers future of SRA737 | Alliance |
21.10.2022 09:10 | GSK | GSK says respiratory vaccine candidate accepted for review in Japan | Alliance |
21.10.2022 07:00 | GSK | RSV older adult vaccine submission in Japan | RNS |